MARKET

ALXN

ALXN

Alexion Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

84.01
-2.13
-2.47%
After Hours: 84.01 0 0.00% 16:56 03/27 EDT
OPEN
85.02
PREV CLOSE
86.14
HIGH
86.62
LOW
83.30
VOLUME
2.54M
TURNOVER
--
52 WEEK HIGH
141.86
52 WEEK LOW
72.67
MARKET CAP
18.60B
P/E (TTM)
7.84
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ALXN and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 23 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ALXN stock price target is 141.05 with a high estimate of 180.00 and a low estimate of 110.00.

EPS

ALXN News

More
  • 3 Dirt-Cheap Healthcare Stocks to Buy Right Now
  • MotleyFool.com · 2d ago
  • Insiders Who Bought The Crash, What It Means For Returns, And My Favorite Pick
  • Seeking Alpha - Article · 2d ago
  • Alexion Pharmaceuticals (ALXN) Gains But Lags Market: What You Should Know
  • Zacks · 3d ago
  • The Top 10 Biotechnology Companies
  • Investopedia · 3d ago

Industry

Pharmaceuticals
-0.41%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About ALXN

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.
More

Webull offers kinds of Alexion Pharmaceuticals, Inc. stock information, including NASDAQ:ALXN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXN stock news, and many more online research tools to help you make informed decisions.